Solasia Pharma K.K. Announces Initiation of Darinaparsin Injection (SP-02) Phase 1 Study
Published: Oct 26, 2011
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (Minato-ku, Tokyo) announced today that enrollment of a Phase I clinical trial evaluating the safety and tolerability of darinaparsin injection (SP-02L) for the treatment of peripheral T-cell lymphoma (PTCL), has commenced in Japan. Darinaparsin is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid cancers. In several studies conducted in the US and other countries, darinaparsin injection has demonstrated good tolerability and safety. In addition, a Phase II study of darinaparsin injection in the US, demonstrated clinical responses in lymphoma, in particular PTCL.